Christian Stanton Schade's Insider Trades & SAST Disclosures
Christian Stanton Schade's most recent trade in Omega Therapeutics Inc was a trade of 25,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Christian Stanton Schade.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Omega Therapeutics Inc | Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Integra Lifesciences Holdi... | Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 8,696 | 63,503 (0%) | 0% | 0 | Common Stock | |
| Omega Therapeutics Inc | Schade Stanton Christian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 512,848 | 512,848 | - | - | Stock Option (Right to Buy) | |
| Omega Therapeutics Inc | Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 36,713 | 36,713 | - | - | Stock Option (Right to Buy) | |
| Omega Therapeutics Inc | Schade Christian Stanton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 36,713 | 36,713 | - | - | Stock Option (Right to Buy) | |
| Integra Lifesciences Holdi... | Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2023 | 4,486 | 54,807 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 47,600 | 47,600 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 32,400 | 259,246 (1%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Christian Stanton Schade | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.81 per share. | 03 Jun 2022 | 65,770 | 226,846 (1%) | 0% | 0.8 | 52,945 | Common Stock |
| Aprea Therapeutics Inc | Christian Stanton Schade | Director, Chairman & CEO | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 18 May 2022 | 37,500 | 292,616 (1%) | 0% | 0.6 | 24,124 | Common Stock |
| Integra Lifesciences Holdi... | Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 3,456 | 50,321 (0%) | 0% | 0 | Common Stock | |
| Integra Lifesciences Holdi... | Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 1,265 | 46,865 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Christian Stanton Schade | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 427,700 | 427,700 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Christian Stanton Schade | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 100,100 | 255,116 (1%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Christian Stanton Schade | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.74 per share. | 25 Feb 2022 | 21,644 | 155,016 (0%) | 0% | 1.7 | 37,661 | Common Stock |
| Integra Lifesciences Holdi... | Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 2,896 | 45,600 (0%) | 0% | 0 | Common Stock | |
| Integra Lifesciences Holdi... | Christian Stanton Schade | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 530 | 42,704 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Christian Stanton Schade | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 329,000 | 329,000 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Christian Stanton Schade | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 88,500 | 176,660 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Christian Stanton Schade | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 77,000 | 77,160 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges